Journal of Semnan University of Medical Sciences
Comparing adverse effects of docetaxel-doxorubicin and paclitaxel-doxorubicin regimens in breast cancer patients
Authors
Abstract
Introduction: Taxanes have emerged as one of the most active agents in the treatment of patients with breast cancer. Nevertheless, questions remain with regard to their toxicity profiles. This study aimed to compare prevalence and severity of adverse effects of two chemotherapy regimens including taxanes (docetaxel or paclitaxel) in breast cancer patients. Materials and Methods: Fifty patients with non-methastatic breast cancer who had received docetaxel-doxorubicin or paclitaxel-doxorubicin regimens included in the study. Adverse drug reactions were recorded from patients' files and graded according to common toxicity criteria. The prevalence and severity of the reactions were compared between two groups of the patients. Results: The prevalence of adverse drug reactions was higher in the patients who received docetaxel-doxorubicin compared to the patients with paclitaxel-doxorubicin regimen (%62.01 vs %37.98). In this account, the patients in docetaxel-doxorubicin group experienced more frequent adverse drug reactions in skin, musculo-skeletal, and blood systems (P
Highlights
Copyright
© 2019, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
Incidence and Cost of Chemotherapy-Induced Adverse Drug Reactions Among Cancer Patients in a Charitable Hospital
Varghese J, Mateti U, Shetty J, Philip ML, Raju BN. Incidence and Cost of Chemotherapy-Induced Adverse Drug Reactions Among Cancer Patients in a Charitable Hospital. J Rep Pharm Sci. 2021;10(1):e147100. doi: https://doi.org/10.4103/jrptps.JRPTPS_68_20
Comparison the Incidence and Severity of Side Effects Profile Of FOLFOX and DCF Regimens in Gastric Cancer Patients
Salehifar E, Avan R, Janbabaei G, Mousavi SK, Faramarzi F. Comparison the Incidence and Severity of Side Effects Profile Of FOLFOX and DCF Regimens in Gastric Cancer Patients. Iran J Pharm Res. 2019;18(2):e126242. doi: https://doi.org/10.22037/ijpr.2019.1100663
A Comparison of 5-HT3 Receptor Antagonist and Metoclopramide in the Patients Receiving Chemotherapeutic Regimens Including CMF, CAF and CHOP
Anvari K, Seilanian-Toussi M, Hosseinzad-Ashkiki H, Shahidsales S. A Comparison of 5-HT3 Receptor Antagonist and Metoclopramide in the Patients Receiving Chemotherapeutic Regimens Including CMF, CAF and CHOP. Int J Cancer Manag. 2015;8(2):e80594. doi:
Comparing Docetaxel Plus Cisplatin with Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer: a Single Institute Study
Khodadad K, Khosravi A, Esfahani-Monfared Z, Karimi S, Seifi S. Comparing Docetaxel Plus Cisplatin with Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer: a Single Institute Study. Iran J Pharm Res. 2014;13(2):e125542. doi: https://doi.org/10.22037/ijpr.2014.1492
Incidence of Chemotherapy-Induced Amenorrhea After Adjuvant Chemotherapy With Taxane and Anthracyclines in Young Patients With Breast Cancer
Pourali L, Taghizadeh kermani A, Ghavamnasiri MR, Khoshroo F, Hosseini S, et al. Incidence of Chemotherapy-Induced Amenorrhea After Adjuvant Chemotherapy With Taxane and Anthracyclines in Young Patients With Breast Cancer. Int J Cancer Manag. 2013;6(3):e80423. doi:
- Scopus by DOI: 0
Last Update: 1 month ago
- Scopus by Title: 2
Last Update: 1 month ago
- Scopus by Title (Ref): 2
Last Update: 1 month ago
- CrossRef: 0
Last Update: 5 hours ago
- OpenAlex: 0
Last Update: 8 hours ago
- OpenCitations: 0
Last Update: 4 days ago